Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Zhang, Haiyan ^a,b   Bernuzzi, Francesca ^a   Lleo, Ana ^a   Ma, Xiong ^b   Invernizzi, Pietro ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b School of Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR;

AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CHEMISTRY; CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; PHYSIOLOGY;

AUTOIMMUNE DISEASES; CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; HUMANS; INTERLEUKIN-17; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION;

EID: 84935035163     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/436450     Document Type: Review

References (131)

1. O. Chazouillères, D. Wendum, L. Serfaty, S. Montembault, O. Rosmorduc, and R. Poupon, "Primary biliary cirrhosisautoimmune hepatitis overlap syndrome: clinical features and response to therapy, " Hepatology, vol. 28, no. 2, pp. 296-301, 1998.
2. K. M. Boberg, R. W. Chapman, G. M. Hirschfield, A. W. Lohse, M. P. Manns, and E. Schrumpf, "Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue, " Journal of Hepatology, vol. 54, no. 2, pp. 374-385, 2011.
3. J. S. Tzartos, M. A. Friese, M. J. Craner et al., "Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis, " The American Journal of Pathology, vol. 172, no. 1, pp. 146-155, 2008.
4. M. A. Lowes, T. Kikuchi, J. Fuentes-Duculan et al., "Psoriasis vulgaris lesions contain discrete populations ofTh1 and Th17 T cells, " Journal of Investigative Dermatology, vol. 128, no. 5, pp. 1207-1211, 2008.
5. G. Azizi, F. Jadidi-Niaragh, and A. Mirshafiey, "Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis, " International journal of rheumatic diseases, vol. 16, no. 3, pp. 243-253, 2013.
6. E. Rouvier, M.-F. Luciani, M.-G. Mattei, F. Denizot, and P. Golstein, "CTLA-8, cloned from an activated T cell, bearing AUrich messenger RNA instability sequences, and homologous to aHerpesvirus saimiri gene, " Journal of Immunology, vol. 150, no. 12, pp. 5445-5456, 1993.
7. T. Starnes, H. E. Broxmeyer, M. J. Robertson, and R. Hromas, "Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis, " The Journal of Immunology, vol. 169, no. 2, pp. 642-646, 2002.
8. J. Lee, W.-H. Ho, M. Maruoka et al., "IL-17E, a novel proinflammatory lig and for the IL-17 receptor homolog IL-17Rh1, " The Journal of Biological Chemistry, vol. 276, no. 2, pp. 1660-1664, 2001.
9. S. G. Hymowitz, E. H. Filvaroff, J. Yin et al., "IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding, " The EMBO Journal, vol. 20, no. 19, pp. 5332-5341, 2001.
10. F. Fossiez, O. Djossou, P. Chomarat et al., "T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines, " Journal of Experimental Medicine, vol. 183, no. 6, pp. 2593-2603, 1996.
11. S. C. Liang, X.-Y. Tan, D. P. Luxenberg et al., "Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, " The Journal of Experimental Medicine, vol. 203, no. 10, pp. 2271-2279, 2006.
12. M. B. M. Teunissen, C. W. Koomen, R. de Waal Malefyt, E. A. Wierenga, and J. D. Bos, "Interleukin-17 and interferon-synergize in the enhancement of proinflammatory cytokine production by human keratinocytes, " Journal of Investigative Dermatology, vol. 111, no. 4, pp. 645-649, 1998.
13. F. Shen, Z. Hu, J. Goswami, and S. L. Gaffen, "Identification of common transcriptional regulatory elements in interleukin-17 target genes, " The Journal of Biological Chemistry, vol. 281, no. 34, pp. 24138-24148, 2006.
14. S. Dragon, M. S. Rahman, Yang J., H. Unruh, A. J. Halayko, and A. S. Gounni, "IL-17 enhances IL-1-mediated CXCL-8 release fromhumanairway smoothmuscle cells, "TheAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 292, no. 4, pp. L1023-L1029, 2007.
15. W. H. Faour, A. Mancini, Q. W. He, and J. A. Di Battista, "Tcell-derived interleukin-17 regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-Activated protein kinase cascade. Role of distal sequences in the 3-untranslated region of COX-2 mRNA, " The Journal of Biological Chemistry, vol. 278, no. 29, pp. 26897-26907, 2003.
16. M. Laan, Z.-H. Cui, H. Hoshino et al., "Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways, " The Journal of Immunology, vol. 162, no. 4, pp. 2347-2352, 1999.
17. Y. Komiyama, S. Nakae, T. Matsuki et al., "IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis, " Journal of Immunology, vol. 177, no. 1, pp. 566-573, 2006.
18. H. R. Conti, F. Shen, N. Nayyar et al., "Th17 cells and IL-17 receptor signaling are essential formucosal host defense against oral c and idiasis, " Journal of ExperimentalMedicine, vol. 206, no. 2, pp. 299-311, 2009.
19. H. Chen, W. Wang, H. Xie et al., "A pathogenic role of IL-17 at the early stage of corneal allograft rejection, " Transplant Immunology, vol. 21, no. 3, pp. 155-161, 2009.
20. W. J. Burlingham, R. B. Love, E. Jankowska-Gan et al., "IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants, " The Journal of Clinical Investigation, vol. 117, no. 11, pp. 3498-3506, 2007.
21. N. Martin-Orozco, P. Muranski, Y. Chung et al., "T helper 17 cells promote cytotoxic T cell activation in tumor immunity, " Immunity, vol. 31, no. 5, pp. 787-798, 2009.
22. T. Starnes, M. J. Robertson, G. Sledge et al., "Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production, " Journal of Immunology, vol. 167, no. 8, pp. 4137-4140, 2001.
23. S. H. Chang and C. Dong, "A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses, " Cell Research, vol. 17, no. 5, pp. 435-440, 2007.
24. S. Aggarwal, N. Ghilardi, M.-H. Xie, F. J. de Sauvage, and A. L. Gurney, "Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17, " Journal of Biological Chemistry, vol. 278, no. 3, pp. 1910-1914, 2003.
25. S. Hue, P. Ahern, S. Buonocore et al., "Interleukin-23 drives innate and T cell-mediated intestinal inflammation, " Journal of Experimental Medicine, vol. 203, no. 11, pp. 2473-2483, 2006.
26. A. V. Rachitskaya, A. M. Hansen, R. Horai et al., "Cutting edge: NKT cells constitutively express IL-23 receptor and RORt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion, " Journal of Immunology, vol. 180, no. 8, pp. 5167-5171, 2008.
27. H. H. Uhlig, B. S. McKenzie, S. Hue et al., "Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology, " Immunity, vol. 25, no. 2, pp. 309-318, 2006.
28. D. J. Cua and C. M. Tato, "Innate IL-17-producing cells: the sentinels of the immune system, " Nature Reviews Immunology, vol. 10, no. 7, pp. 479-489, 2010.
29. S. L. Gaffen, "Structure and signalling in the IL-17 receptor family, " Nature Reviews Immunology, vol. 9, no. 8, pp. 556-567, 2009.
30. H. Ishigame, S. Kakuta, T. Nagai et al., "Differential roles of interleukin-17A and -17F in host defense againstmucoepithelial bacterial infection and allergic responses, " Immunity, vol. 30, no. 1, pp. 108-119, 2009.
31. N. Hizawa, M. Kawaguchi, S.-K. Huang, and M. Nishimura, "Role of interleukin-17F in chronic inflammatory and allergic lung disease, " Clinical and Experimental Allergy, vol. 36, no. 9, pp. 1109-1114, 2006.
32. X. O. Yang, S. H. Chang, H. Park et al., "Regulation of inflammatory responses by IL-17F, " Journal of Experimental Medicine, vol. 205, no. 5, pp. 1063-1075, 2008.
33. Y.-H. Wang, P. Angkasekwinai, N. Lu et al., "IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-ActivatedTh2memory cells, "TheJournal of Experimental Medicine, vol. 204, no. 8, pp. 1837-1847, 2007.
34. T. Sharkhuu, K. I. Matthaei, E. Forbes et al., "Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity, " Clinical and ExperimentalAllergy, vol. 36, no. 12, pp. 1575-1583, 2006.
35. J. L. Barlow and A. N. J. McKenzie, "IL-25: a key requirement for the regulation of type-2 immunity, " BioFactors, vol. 35, no. 2, pp. 178-182, 2009.
36. H. Li, J. Chen, A. Huang et al., "Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 773-778, 2000.
37. L. vanMaele, C. Carnoy, D. Cayet et al., "TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3CD127+ immune cells in spleen and mucosa, " Journal of Immunology, vol. 185, no. 2, pp. 1177-1185, 2010.
38. D. B. Holl and , R. A. Bojar, M. D. Farrar, and K. T. Holl and , "Differential innate immune responses of a living skin equivalent model colonized by Staphylococcus epidermidis or Staphylococcus aureus, " FEMSMicrobiology Letters, vol. 290, no. 2, pp. 149-155, 2009.
39. Y. Yamaguchi, K. Fujio, H. Shoda et al., "IL-17B and IL-17C are associated with TNF-production and contribute to the exacerbation of inflammatory arthritis, " The Journal of Immunology, vol. 179, no. 10, pp. 7128-7136, 2007.
40. Z. Yao, W. C. Fanslow, M. F. Seldin et al., "Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor, " Immunity, vol. 3, no. 6, pp. 811-821, 1995.
41. Z. Yao, M. K. Spriggs, J. M. J. Derry et al., "Molecular characterization of the human interleukin (IL)-17 receptor, " Cytokine, vol. 9, no. 11, pp. 794-800, 1997.
42. Y. Sonobe, H. Takeuchi, K. Kataoka et al., "Interleukin-25 expressed by brain capillary endothelial cells maintains bloodbrain barrier function in a protein kinase C-dependent manner, " The Journal of Biological Chemistry, vol. 284, no. 46, pp. 31834-31842, 2009.
43. S. Lajoie-Kadoch, P. Joubert, S. Letuve et al., "TNF-And IFN-inversely modulate expression of the IL-17E receptor in airway smooth muscle cells, " The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 290, no. 6, pp. L1238-L1246, 2006.
44. A. Terashima, H. Watarai, S. Inoue et al., "A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity, " Journal of Experimental Medicine, vol. 205, no. 12, pp. 2727-2733, 2008.
45. E. A. Rickel, L. A. Siegel, P. Y. Bo-Rin et al., "Identification of functional roles for both IL-17RB and IL-17RA inmediating IL-25-induced activities, " The Journal of Immunology, vol. 181, no. 6, pp. 4299-4310, 2008.
46. R. E. Kuestner, D.W. Taft, A. Haran et al., "Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F, " The Journal of Immunology, vol. 179, no. 8, pp. 5462-5473, 2007.
47. D. Ge and Z. You, "Expression of interleukin-17RC protein in normal human tissues, " International Archives of Medicine, vol. 1, no. 1, article 19, 2008.
48. Z. Rong, A. Wang, Z. Li et al., "IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling, " Cell Research, vol. 19, no. 2, pp. 208-215, 2009.
49. T.-S. Li, X.-N. Li, Z.-J. Chang, X.-Y. Fu, and L. Liu, "Identification and functional characterization of a novel interleukin 17 receptor: a possible mitogenic activation through ras/mitogenactivated protein kinase signaling pathway, " Cellular Signalling, vol. 18, no. 8, pp. 1287-1298, 2006.
50. T. A. Moseley, D. R. Haudenschild, L. Rose, and A. H. Reddi, "Interleukin-17 family and IL-17 receptors, " Cytokine and Growth Factor Reviews, vol. 14, no. 2, pp. 155-174, 2003.
51. A. Hot and P. Miossec, "Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes, " Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 727-732, 2011.
52. S. Zhu, W. Pan, P. Shi et al., "Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling, " The Journal of Experimental Medicine, vol. 207, no. 12, pp. 2647-2662, 2010.
53. L. Zhao, Y. Tang, Z. You et al., "Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression, " PLoS ONE, vol. 6, no. 4, Article ID e18909, 2011.
54. H. Yu, J. Huang, Y. Liu et al., "IL-17 contributes to autoimmune hepatitis, " Journal of Huazhong University of Science and Technology [Medical Sciences], vol. 30, no. 4, pp. 443-446, 2010.
55. C. R. Grant, R. Liberal, B. S. Holder et al., "Dysfunctional CD39regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis, " Hepatology, vol. 59, no. 3, pp. 1007-1015, 2014.
56. M. S. Longhi, R. Liberal, B. Holder et al., "Inhibition of interleukin-17 promotes differentiation of CD25-cells into stable T regulatory cells in patients with autoimmune hepatitis, " Gastroenterology, vol. 142, no. 7, pp. 1526.e6-1535.e6, 2012.
57. M. P. Manns, A. J. Czaja, J. D. Gorham et al., "Diagnosis and management of autoimmune hepatitis, " Hepatology, vol. 51, no. 6, pp. 2193-2213, 2010.
58. C. Qian, T. Jiang, W. Zhang et al., "Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis, " Cytokine, vol. 64, no. 1, pp. 172-180, 2013.
59. R. Y. Z. Lan, T. L. Salunga, K. Tsuneyama et al., "Hepatic IL-17 responses in human and murine primary biliary cirrhosis, " Journal of Autoimmunity, vol. 32, no. 1, pp. 43-51, 2009.
60. K. Harada, S. Shimoda, Y. Sato, K. Isse, H. Ikeda, and Y. Nakanuma, "Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis, " Clinical and Experimental Immunology, vol. 157, no. 2, pp. 261-270, 2009.
61. C.-Y. Yang, X. Ma, K. Tsuneyama et al., "IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy, " Hepatology, vol. 59, no. 5, pp. 1944-1953, 2014.
62. K. Harada, S. Shimoda, H. Ikeda et al., "Significance of periductal Langerhans cells and biliary epithelial cell-derived macrophage inflammatory protein-3 in the pathogenesis of primary biliary cirrhosis, " Liver International, vol. 31, no. 2, pp. 245-253, 2011.
63. W. Hsu, W. Zhang, K. Tsuneyama et al., "Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2R -/-mice, " Hepatology, vol. 49, no. 1, pp. 133-140, 2009.
64. K. Kawata, M. Tsuda, G.-X. Yang et al., "Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis, " PLoS ONE, vol. 8, no. 9, Article ID e74225, 2013.
65. C.-Y. Yang, P. S. C. Leung, G.-X. Yang et al., "Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent, " Clinical and Experimental Immunology, vol. 168, no. 3, pp. 261-267, 2012.
66. J. Katt, D. Schwinge, T. Schoknecht et al., "Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis, " Hepatology, vol. 58, no. 3, pp. 1084-1093, 2013.
67. H. Kulaksiz, G. Rudolph, P. Kloeters-Plachky, P. Sauer, H. Geiss, and A. Stiehl, "Biliaryc and ida infections in primary sclerosing cholangitis, " Journal of Hepatology, vol. 45, no. 5, pp. 711-716, 2006.
68. F. Meng, K. Wang, T. Aoyama et al., "Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice, " Gastroenterology, vol. 143, no. 3, pp. 765-776, 2012.
69. M. Hara, H. Kono, S. Furuya, K. Hirayama, M. Tsuchiya, and H. Fujii, "Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice, " Journal of Surgical Research, vol. 183, no. 2, pp. 574-582, 2013.
70. Y. Zheng, D. M. Danilenko, P. Valdez et al., "Interleukin-22, a T17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis, " Nature, vol. 445, no. 7128, pp. 648-651, 2007.
71. A. Ogawa, A. and oh, Y. Araki, T. Bamba, and Y. Fujiyama, "Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice, " Clinical Immunology, vol. 110, no. 1, pp. 55-62, 2004.
72. E. Lubberts, M. I. Koenders, B. Oppers-Walgreen et al., "Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion, " Arthritis and Rheumatism, vol. 50, no. 2, pp. 650-659, 2004.
73. H.-C. Hsu, P. Yang, J. Wang et al., "Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice, " Nature Immunology, vol. 9, no. 2, pp. 166-175, 2008.
74. M. S. Longhi, Y. Ma, G. Mieli-Vergani, and D. Vergani, "Aetiopathogenesis of autoimmune hepatitis, " Journal of Autoimmunity, vol. 34, no. 1, pp. 7-14, 2010.
75. I. N. Crispe, "The liver as a lymphoid organ, " Annual Review of Immunology, vol. 27, pp. 147-163, 2009.
76. M. S. Longhi, M. J. Hussain, R. R. Mitry et al., "Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis, " The Journal of Immunology, vol. 176, no. 7, pp. 4484-4491, 2006.
77. S. Ferri, M. S. Longhi, C. de Molo et al., "A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis, " Hepatology, vol. 52, no. 3, pp.999-1007, 2010.
78. S. Sakaguchi, K. Fukuma, K. Kuribayashi, and T. Masuda, "Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-Tolerance; deficit of a T cell subset as a possible cause of autoimmune disease, " The Journal of Experimental Medicine, vol. 161, no. 1, pp. 72-87, 1985.
79. J. M. Fletcher, R. Lonergan, L. Costelloe et al., "CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis, " Journal of Immunology, vol. 183, no. 11, pp. 7602-7610, 2009.
80. M. S. Longhi, F. Meda, P. Wang et al., "Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis, " Hepatology, vol. 47, no. 2, pp. 581-591, 2008.
81. P. Invernizzi, C. Selmi, and M. E. Gershwin, "Update on primary biliary cirrhosis, " Digestive and Liver Disease, vol. 42, no. 6, pp. 401-408, 2010.
82. K. D. Lindor, M. E. Gershwin, R. Poupon, M. Kaplan, N. V. Bergasa, and E. J. Heathcote, "Primary biliary cirrhosis, " Hepatology, vol. 50, no. 1, pp. 291-308, 2009.
83. G. Syal, M. Fausther, and J. A. Dranoff, "Advances in cholangiocyte immunobiology, "TheAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 303, no. 10, pp. G1077-G1086, 2012.
84. G. Ballardini, M. Fallani, F. B. Bianchi, and E. Pisi, "Antigen presenting cells in liver biopsies from patients with primary biliary cirrhosis, " Autoimmunity, vol. 3, no. 2, pp. 135-144, 1989.
85. S. Oertelt, Z.-X. Lian, C.-M. Cheng et al., "Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-receptor II dominant-negative mice, " The Journal of Immunology, vol. 177, no. 3, pp. 1655-1660, 2006.
86. M. Nakamura, H. Kondo, T. Mori et al., "Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis, " Hepatology, vol. 45, no. 1, pp. 118-127, 2007.
87. S. Itoh, T. Ichida, T. Yoshida et al., "Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis, " Journal of Gastroenterology and Hepatology, vol. 13, no. 3, pp. 257-265, 1998.
88. Y.-M. Lee and M. M. Kaplan, "Primary sclerosing cholangitis, " The New England Journal of Medicine, vol. 332, no. 14, pp. 924-933, 1995.
89. P. Angulo and K. D. Lindor, "Primary sclerosing cholangitis, " Hepatology, vol. 30, no. 1, pp. 325-332, 1999.
90. J. E. Eaton, J. A. Talwalkar, K. N. Lazaridis, G. J. Gores, and K. D. Lindor, "Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management, " Gastroenterology, vol. 145, no. 3, pp. 521-536, 2013.
91. G.M. Hirschfield, T. H. Karlsen, K. D. Lindor, and D. H. Adams, "Primary sclerosing cholangitis, " The Lancet, vol. 382, no. 9904, pp. 1587-1599, 2013.
92. G. Rudolph, D. Gotthardt, P. Kloters-Plachky, H. Kulaksiz, D. Rost, and A. Stiehl, "Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis, " Journal of Hepatology, vol. 51, no. 1, pp. 149-155, 2009.
93. P. Fickert, G. Zollner, A. Fuchsbichler et al., "Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles, " Gastroenterology, vol. 123, no. 4, pp. 1238-1251, 2002.
94. M. J. Pollheimer, M. Trauner, and P. Fickert, "Willwe evermodel PSC?-its hard to be a PSC model!, " Clinics and Research in Hepatology and Gastroenterology, vol. 35, no. 12, pp. 792-804, 2011.
95. A. Chiricozzi, E. Guttman-Yassky, M. Suárez-Farias et al., "Integrative responses to IL-17 and TNF-in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis, " Journal of Investigative Dermatology, vol. 131, no. 3, pp. 677-687, 2011.
96. S. Fujino, A. and oh, S. Bamba et al., "Increased expression of interleukin 17 in inflammatory bowel disease, " Gut, vol. 52, no. 1, pp. 65-70, 2003.
97. S. Kotake, N. Udagawa, N. Takahashi et al., "IL-17 in synovial fluids frompatients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, "The Journal of Clinical Investigation, vol. 103, no. 9, pp. 1345-1352, 1999.
98. G. Dong, R. Ye, W. Shi et al., "IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients, " Chinese Medical Journal, vol. 116, no. 4, pp. 543-548, 2003.
99. S. Zhu and Y. Qian, "IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential, " Clinical Science, vol. 122, no. 11, pp. 487-511, 2012.
100. K. A. Papp, R. G. Langley, B. Sigurgeirsson et al., "Efficacy and safety of secukinumab in the treatment of moderate-Tosevere plaque psoriasis: a r and omized, double-blind, placebocontrolled phase II dose-ranging study, " British Journal of Dermatology, vol. 168, no. 2, pp. 412-421, 2013.
101. C. Leonardi, R. Matheson, C. Zachariae et al., "Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis, " The New Engl and Journal of Medicine, vol. 366, no. 13, pp. 1190-1191, 2012.
102. K. A. Papp, C. Leonardi, A. Menter et al., "Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis, " The New Engl and Journal ofMedicine, vol. 366, no. 13, pp. 1181-1189, 2012.
103. M. T. Tse, "IL-17 antibodies gain momentum, " Nature Reviews Drug Discovery, vol. 12, no. 11, pp. 815-816, 2013.
104. M. C. Genovese, P. Durez, H. B. Richards et al., "Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, r and omised, placebo controlled study, " Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 863-869, 2013.
105. D. Baeten, X. Baraliakos, J. Braun et al., "Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: arandomised, double-blind, placebo-controlled trial, " The Lancet, vol. 382, pp. 1705-1713, 2013.
106. A.D. Dick, I. Tugal-Tutkun, S. Foster et al., "Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials, " Ophthalmology, vol. 120, no. 4, pp. 777-787, 2013.
107. M. C. Genovese, M. Greenwald, C. S. Cho et al., "A phase II randomized study of subcutaneous ixekizumab, an antiinterleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors, " Arthritis & Rheumatism, vol. 66, no. 7, pp. 1693-1704, 2014.
108. W. Hueber, B. E. Sands, S. Lewitzky et al., "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: Unexpected results of arandomised, double-blindplacebo-controlled trial, " Gut, vol. 61, no. 12, pp. 1693-1700, 2012.
109. D. Toy, D. Kugler, M. Wolfson et al., "Cutting edge: interleukin 17 signals through a heteromeric receptor complex, " Journal of Immunology, vol. 177, no. 1, pp. 36-39, 2006.
110. S. Zrioual, M.-L. Toh, A. Tournadre et al., "IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood, " Journal of Immunology, vol. 180, no. 1, pp. 655-663, 2008.
111. R. Pappu, V. Ramirez-Carrozzi, N. Ota, W. Ouyang, and Y. Hu, "The IL-17 family cytokines in immunity and disease, " Journal of Clinical Immunology, vol. 30, no. 2, pp. 185-195, 2010.
112. C. Ritchlin, P. Rahman, A. Kavanaugh et al., "Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological anti-Tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, doubleblind, placebo-controlled, " Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 990-999, 2014.
113. W. J. S and born, C. Gasink, L.-L. Gao et al., "Ustekinumab induction and maintenance therapy in refractory Crohns disease, " The New Engl and Journal of Medicine, vol. 367, no. 16, pp. 1519-1528, 2012.
114. C. E. M. Griffiths, B. E. Strober, P. van de Kerkhof et al., "Comparison of ustekinumab and etanercept for moderate-Tosevere psoriasis, "The New Engl and Journal ofMedicine, vol. 362, no. 2, pp. 118-128, 2010.
115. K. A. Papp, C. E. M. Griffiths, K. Gordon et al., "Long-Term safety of ustekinumab in patients with moderate-To-severe psoriasis: final results from 5 years of follow-up, " British Journal of Dermatology, vol. 168, no. 4, pp. 844-854, 2013.
116. P. Miossec and J. K. Kolls, "Targeting IL-17 and T17 cells in chronic inflammation, " Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763-776, 2012.
117. A. Shetty, R. Hanson, P. Korsten et al., "Tocilizumab in the treatment of rheumatoid arthritis and beyond, " Drug Design, Development and Therapy, vol. 8, pp. 349-364, 2014.
118. J. E. Frampton, "Tocilizumab: a reviewof its use in the treatment of juvenile idiopathic arthritis, " PediatricDrugs, vol. 15, no. 6, pp. 515-531, 2013.
119. M. Geyer and U. Müller-Ladner, "Actual status of antiinterleukin-1 therapies in rheumatic diseases, " Current Opinion in Rheumatology, vol. 22, no. 3, pp. 246-251, 2010.
120. J. R. Huh, E. E. Englund, H. Wang et al., "Identification of potent and selective diphenylpropanamide RORinhibitors, " ACS Medicinal Chemistry Letters, vol. 4, no. 1, pp. 79-84, 2013.
121. P. M. Khan, B. E.-D. M. El-Gendy, N. Kumar et al., "Small molecule amides as potent ROR-selective modulators, " Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 2, pp. 532-536, 2013.
122. S. C. P. Williams, "Flurry of deal-making surrounds new autoimmunity target, " Nature Medicine, vol. 19, no. 9, article 1078, 2013.
123. L. A. Solt, N. Kumar, P. Nuhant et al., "Suppression of TH17 differentiation and autoimmunity by a synthetic ROR lig and , " Nature, vol. 472, no. 7344, pp. 491-494, 2011.
124. P. Delerive, W. W. Chin, and C. S. Suen, "Identification of Reverb as a novel ROR target gene, " Journal of Biological Chemistry, vol. 277, no. 38, pp. 35013-35018, 2002.
125. J. Wang, L. Yin, and M. A. Lazar, "The orphan nuclear receptor Rev-erb regulates circadian expression of plasminogen activator inhibitor type 1, "The Journal of Biological Chemistry, vol. 281, no. 45, pp. 33842-33848, 2006.
126. T. Wada, S. K. Hong, M. Angers et al., "Identification of oxysterol 7-hydroxylase (Cyp7b1) as a novel retinoid-related orphan receptor (ROR) (NR1F1) target gene and a functional cross-Talk between ROR and liver X receptor (NR1H3), " Molecular Pharmacology, vol. 73, no. 3, pp. 891-899, 2008.
127. N. Kumar, B. Lyda, M. R. Chang et al., "Identification of SR2211: a potent synthetic ROR-selective modulator, " ACS Chemical Biology, vol. 7, no. 4, pp. 672-677, 2012.
128. E. ELinghaus, D. ELinghaus, P. E. Stuart et al., "Genome-wide asociation study identifies a psoriasis susceptibility locus at TRAF3IP2, " Nature Genetics, vol. 42, no. 11, pp. 991-995, 2010.
129. U. Hüffmeier, S. Uebe, A. B. Ekici et al., "CoMon variants at TRAF3IP2 are aSociated with susceptibility to psoriatic arthritis and psoriasis, "NatureGenetics, vol. 42, no. 11, pp. 996-999, 2010.
130. C. Liu, S. Swaidani, W. Qian et al., "A CC loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17-And IL-25-induced inflammation, " Science Signaling, vol. 4, no. 197, article ra72, 2011.
131. F. Shen and S. L. Gaffen, "Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy, " Cytokine, vol. 41, no. 2, pp. 92-104, 2008.